Nanoscope Therapeutics announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted both Sakigake and Orphan Drug designations to MCO-010, the company’s lead investigational therapy for patients with severe vision loss caused by inherited retinal diseases (IRDs).

Sakigake is Japan’s premier fast-track regulatory designation for innovative therapies addressing serious unmet medical needs. The program is intended to accelerate patient access to breakthrough treatments through prioritized regulatory consultation and review, often targeting a 6-month review timeline, in close collaboration with the Pharmaceuticals and Medical Devices Agency (PMDA). Sakigake designation may also support premium pricing following approval. When combined with Orphan Drug designation—granted to therapies intended for fewer than 50,000 patients with high unmet medical need—the decision establishes a strong and expedited regulatory pathway for MCO-010 in Japan.

MCO-010 is the first retinal gene therapy to receive both Sakigake and Orphan Drug designations in Japan.

“These designations from Japan’s MHLW mark another pivotal milestone for Nanoscope,” said Samarendra Mohanty, PhD, president and chief scientific officer of Nanoscope Therapeutics. “Sakigake recognition underscores the novelty of MCO-010 as a one-time, in-office intravitreal optogenetic therapy and its potential to address profound vision loss where no approved treatments exist. Together with our progress in the US and Europe, we are advancing one of the most comprehensive global regulatory strategies in optogenetic retinal gene therapy for patients living with inherited retinal diseases.”

In the European Union, the European Medicines Agency (EMA) has granted five Orphan Drug designations covering non-syndromic and syndromic rod- and cone-dominant dystrophies, as well as macular dystrophies. In the United States, the FDA has awarded Orphan Drug and Fast Track designations for retinitis pigmentosa (RP), and Orphan Drug, Fast Track, and Regenerative Medicine Advanced Therapy (RMAT) designations for Stargardt disease (SD).

In addition, the FDA, EMA, and PMDA have conditionally approved the brand name Mogenry for MCO-010. Nanoscope continues to advance its rolling Biologics License Application (BLA) with the FDA for marketing approval of MCO-010 for RP patients in the United States.